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ATPase activityHsp90 forms a variety of complexes differing both in clientele and co-chaperones. Central to the role of co-
chaperones in the formation of Hsp90 complexes is the delivery of client proteins and the regulation of the
ATPase activity of Hsp90. Determining themechanisms by which co-chaperones regulate Hsp90 is essential in
understanding the assembly of these complexes and the activation and maturation of Hsp90's clientele.
Mechanistically, co-chaperones alter the kinetics of the ATP-coupled conformational changes of Hsp90. The
structural changes leading to the formation of a catalytically active unit involve all regions of the Hsp90 dimer.
Their complexity has allowed different orthologues of Hsp90 to evolve kinetically in slightly different ways.
The interaction of the cytosolic Hsp90 with a variety of co-chaperones lends itself to a complex set of different
regulatory mechanisms that modulate Hsp90's conformation and ATPase activity. It also appears that the
conformational switches of Hsp90 are not necessarily coupled under all circumstances. Here, I described
different co-chaperone complexes and then discuss in detail the mechanisms and role that speciﬁc co-
chaperones play in this. I will also discuss emerging evidence that post-translational modiﬁcations also affect
the ATPase activity of Hsp90, and thus complex formation. Finally, I will present evidence showing how
Hsp90's active site, although being highly conserved, can be altered to show resistance to drug binding, but
still maintain ATP binding and ATPase activity. Such changes are therefore unlikely to signiﬁcantly alter
Hsp90's interactions with client proteins and co-chaperones. This article is part of a Special Issue entitled:
Heat Shock Protein 90 (HSP90).hock Protein 90 (HSP90).
 license. © 2011 Elsevier B.V. Open access under CC BY license. 1. Introduction
Hsp90 is an essential molecular chaperone required for the mainte-
nance, activation or maturation of speciﬁc client proteins. Many of these
clients are some of the most important proteins involved in signal
transduction pathways. They include proteins such as BRaf, ErbB2, Cdk4,
and steroid hormone receptors aswell as structural proteins such as actin
and tubulin (see http://www.picard.ch/Downloads/Hsp90interactors.
pdf). The versatility of the Hsp90 system has also enabled viral proteins
inmany instances to recruit Hsp90 as a chaperone for their ownneeds [1].
Because Hsp90 is responsible for the activation of such a structurally
diverse range of proteins it has evolved to form a variety of complexes
each with speciﬁc co-chaperones that regulate its ATPase coupled
conformational changes.
Understanding the mechanism of ATP hydrolysis is crucial to
understanding the role that Hsp90 co-chaperones play and ultimately
the mechanism of client protein activation. Direct evidence for this
controversial activity [2–4] came from the crystal structure of the N-
terminal domain of the saccharomyces cerevisiae Hsp90 in complex with
ADP, which identiﬁed that the essential residues for ATP catalysis were
conserved [5]. The focus then moved on to the precise mechanism bywhich ATP is hydrolyzed [6–9]. Support for the rate-limiting step being
structural change [9], rather thanATPhydrolysis [6], emerged fromthe co-
crystal structurebetween themiddledomainofHsp90and theN-terminal
domain of Aha1 [8]. Aha1 was seen to modulate the so-called catalytic
loop of the middle domain of Hsp90 and therefore activate its ATPase
activity. Categorical evidence that the formation of catalytically active
units ofHsp90 involve a series of complex conformational changes [7]was
seen with the full-length structure of Hsp90 in its closed N-terminally
dimerized state, stabilized by Sba1 bound between its N-terminal
domains [10] (Fig. 1a–b). This revealed the structural changes that form
the catalytically active state involve a complicated process of conforma-
tional switches indifferent regions of theprotein,which together conspire
to assemble the active state [7,9–11]. It is now apparent that all Hsp90
homologs can hydrolyze ATP [12–15]. To understand the role of co-
chaperones in Hsp90 complexes it is essential to understand the
conformational cycle of Hsp90. Thus, I will give a brief outline of the
ATP-coupled structural changes of Hsp90 before discussing the role of co-
chaperones in Hsp90.
2. Structural changes and the catalytic unit of Hsp90
To achieve a closed catalytically active state, Hsp90 initially
undergoes a structural rearrangement of its ATP lids, represented by
residues Gly 94 to Gly 121 (S. cerevisiae numbering), which close over
the bound ATP. The restructuring of this segment disrupts the packing
Fig. 1. The catalytically active unit of Hsp90. a), Pymol cartoon of the Hsp90 dimer (pdb,
2CG9; Sba1 not shown). N-terminal domains (N) are in green and magenta, middle
domains (M) in gold and yellow and the C-terminal domains (C) in salmon and blue.
AMPPNP is shown as spheres bound to the N-terminal domains. b), Stabilization of the
N-terminal domains of Hsp90 in their dimerized state by Sba1 (pdb, 2CG9). Sba1 is
shown in cyan bound between the dimerised N-terminal domains of Hsp90 (green and
magenta). The ATP lids (red) are in their closed conformation. α-helix 1 and β-strand 1,
which undergo an exchange of position are indicated. AMPPNP is shown as spheres. c),
Stabilization of the catalytic loop (yellow with yellow residues) by interaction between
Thr 22 of the neighboring N-terminal domain (pale green with green residues) and Leu
378 of the catalytic loop and between Ile 117 of the ATP lid (yellow with cyan residues)
and Leu 374 of the catalytic loop of the same monomer (pdb, 2CG9). Hydrogen bonds
between the catalytic Arg 380 and AMPPNP are shownwith dotted blue lines. d), Model
of the domain interface between the N-terminal- and middle-domain of Hsp90
showing that the catalytic loop may remain in a closed inactive state and is thus not
coupled to other structural changes resulting from the closed dimerized state of Hsp90.
The middle domain (pdb, 1HK7; yellow) with a closed catalytic loop (cyan, except for
Arg 380 which is shown in gold) was superimposed on the full-length closed Hsp90
structure (pdb, 2CG9; N-domain, magenta;middle domain, green). No steric clashes are
observed and a number of hydrogen bonds can be formed, which are shown as dotted
blue lines. Water molecules are shown as cyan spheres.
Fig. 2. Kinetic cycles of the S. cerevisiae Hsp90 and E. coli Htpg. In the yeast cycle (blue
and black arrows) the conformational changes leading to the catalytically active state
(Closed-ATP-Active) involves transition via two intermediate conformations (I1 and I2).
Aha1 is supposed to accelerate the cycle by bypassing the I1 sate. In the E. coli cycle (red
and black arrows) a two-phase transition via an intermediate state (I) leads to the
closed active (T) state. The slowest step in the cycles, both representing conformational
change, are indicated. The open, closed and active state as well as the nucleotide state of
the chaperone throughout the cycle is indicated.
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allows this helix and β-strand 1, residues 1 to 27, of each monomer of
Hsp90 to remodel as part of an exchange between the N-terminal
domains that occurs during dimerization (Fig. 1a–b). The reposition-
ing ofα-helix 1 is important as it sets up the dimerization interface for
the N-terminal domains (Fig. 1b). Furthermore, the ATP lid in the
closed state allows the catalytic loop residue (Arg 380) of the middle
domain access to the ATP-binding site. The ATP lid in the closed
position also helps to stabilize the catalytic loop in its open activestate, bymaking a hydrophobic contact between its Ile 117 amino acid
residue and Leu 374 of the catalytic loop (Fig. 1c). In addition, the
repositioning of α-helix 1 allows its Thr 22 residue to interact with
Leu 378 of the catalytic loop of the neighboring Hsp90 monomer and
thereby stabilize it in an active state (Fig. 1c).
Recent kinetic analysis [16,17] lends support to the rate-limiting
step of ATP turnover being conformational change rather than ATP
hydrolysis [6]. The ﬁrst of these models [17] suggests that following
binding of ATP to yeast Hsp90, the conformational changes leading to
the catalytically active state involves a transition to two intermediate
conformations (Fig. 2). The ﬁrst, I1, results from ATP lid closure and
release of the N-terminal segment of the N-terminal domain and has
the lowest rate constant. I2 is then formed through dimerization of the
N-domains. Finally, a third transition to the catalytically active state
occurs by association of the N- and middle-domains and presumably
interaction of ATP with the catalytic loop. The ATP is now trapped and
committed to hydrolysis. In this model Aha1 bypasses the formation
of the I1 state, thus presumably accelerating the rate-limiting step of
the reaction. In another model, binding of ATP to the Escherichia Coli
Hsp90 homolog, HtpG, leads to a two-phase transition, a rapid change
to an intermediate state followed by a slower transition to the T
(closed) state (Fig. 2). Interestingly, HtpG lacks an equivalent Aha1
homolog, which might account for this difference, assuming all states
have been identiﬁed.
The above model suggests that Aha1 modulates speciﬁc early
conformational switches that accelerate the rate-limiting step of the
cycle? However, this might not be as simple as it appears at ﬁrst sight.
The activation of the Hsp90 ATPase activity by full-length Aha1 is
signiﬁcantly stronger than that by the N-terminal domain alone [15].
Thus, it is clear that Aha1 has additional affects on Hsp90 that have not
as yet been structurally characterized. However, the N-terminal
domain of Aha1 in complex with the middle domain of Hsp90 shows
that Aha1 releases the catalytic loop of the middle domain, but this
step seems to be, at least in the absence of Aha1, a late step
conformational change. Furthermore, release of the catalytic loop
might in itself inﬂuence earlier steps in the cycle, thus altering the
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the precise details of the kinetics can vary due to changes in speciﬁc
conformational switches of Hsp90 under different conditions. Cur-
rently, evidence suggests that Aha1 acts to modulate a number of
different stages in the cycle. It could act directly to release the ATP lid
either by displacing it or indirectly by modulation of the N-terminal
sequence (β-strand 1 and α-helix 1) of the N-terminal domain that is
intimately associated with the ATP lid. Alternatively, it might provide
stability for the associating N-terminal domains during dimerization
and or the association of the N- tomiddle-domains. Noteworthy, is the
ability of Aha1 to suppress the F349A mutation, which is found in the
N- andmiddle-domain interface, thus indicating that Aha1might play
a role in stabilizing the association of these domains. In fact, the
binding of Aha1 on both the N- and middle-domains of Hsp90 [8,18]
suggests that the domains of Hsp90 need to be closely associated for
the complete Aha1–Hsp90 association to occur. It is also interesting to
note that the association of the N- and middle-domains brings the N-
terminal segments of the N-terminal domains close to the catalytic
loops in their closed state. In fact, in the closed state the catalytic loops
may potentially become hydrogen bonded to the N-terminal domains
(Fig. 1d). Thus, the simplest function of the N-terminal domain of
Aha1 appears to be as an activator of Hsp90 ATPase activity by
destabilizing not only the interactions of the catalytic loop with the
middle domain of Hsp90, but possibly also with the N-terminal
domains of the chaperone.
The series of conformational switches or structural changes
required to form the catalytically active state of Hsp90 makes it
ideal for regulation by a variety of different co-chaperones. This is
achieved by modulation of the individual switches of Hsp90. It also
suggests that the conformational changes that occur in Hsp90may not
necessarily be coupled under all circumstances. This has been
demonstrated in at least two different ways. Firstly, the activation of
Hsp90 by full-length Aha1 and the N-terminal domain of Aha1 (or
Hch1) do not stimulate the ATPase activity of Hsp90 to the same
degree. Since full-length Aha1 stimulates Hsp90 ATPase far more so
than the N-terminal domain alone, then it follows that other
conformational changes required to achieve the fully active state
might not be necessarily coupled to the movement of the catalytic
loop. Secondly, Rar1 can activate Hsp90 in an open state. In this case it
is assumed that the catalytic loop of Hsp90 is involved in the catalysis
of ATP, but clearly not dependent on ATP lid closure and N-terminal
dimerization. Such a system of conformational switches makes Hsp90
ideal for a variety of different regulatory mechanisms to operate and
thus modulate the Hsp90 cycle in a tailored fashion that suits the
maturation or activation of its client protein.
While the human and yeast Hsp90 systems appear to be similar
there are some differences seen with the kinetics of the Trap1 and
Grp94 orthologues. For Trap1 the rate-limiting step appears not to
have yet been settled and is either hydrolysis or conformational
change. However, whatever the situation commitment to hydrolysis
appears to be absent [14]. Grp94 also lacks trapping of the bound ATP
and commitment to hydrolysis [13]. These differences in the ATPase
cycle may have evolved due to the differing requirements and co-
chaperone associations and thus the speciﬁc regulation that Hsp90 is
subject to.
3. Co-chaperone modulation of the catalytic unit
3.1. Sti1/Hop
The co-chaperone Sti1/Hop is responsible for the delivery of client
proteins, such as steroid hormone receptors, to Hsp90 in a system that
also involves the chaperone Hsp70. Regulation of the ATPase activity
of Hsp90 was ﬁrst shown with the potent inhibitor Sti1 [19]. The lack
of a high resolution structure of Hop/Sti1 in complex with Hsp90 has
held back our understanding of how this co-chaperone regulates theATPase activity of Hsp90, although it is well established that the
primary binding site is the MEEVD motif, at the extreme C-terminus,
of Hsp90 [20]. Initial, biochemical and structural studies, with the
yeast and human protein reveled additional contacts to the C-
terminal-, middle- and N-terminal-domains of Hsp90 [19,21,22].
Using the structure of the individual domains a model was
reconstructed that showed Hop to be a dimer, as previously suggested
[19,23], and to have a butterﬂy like conformation (Fig. 3) [21]. The
TPR2A domain was shown to be the main dimerization interface,
which is consistent with previous work [19]. However, recent
evidence has emerged that supports multiple interaction sites
between Hop and Hsp90 [24] and suggests that for Hop each
monomer can bind to Hsp90 independently [24]. Thus, it is
conceivable that Hop can exist as a dimer, but its interaction with
Hsp90 is as monomeric units [24] (Fig. 3). However, this study does
conﬁrm that Hop has multiple interaction sites with the C-terminal,
middle- and N-terminal-domains of Hsp90, and thus supports
previous studies showing that Sti1 is able to interact with the ﬁrst
24 amino acid residues of the N-terminal domain and thus prevent its
dimerization [22]. Furthermore, the formation of Hsp90 complexes
bound with a single Hop monomer supports the ﬁnding that a single
Hop molecule can inhibit the ATPase activity of Hsp90, while
simultaneously allowing access of immunophillins and progression
of the chaperone cycle [25]. Interestingly, the addition of AMPPNP to a
Cpr6–Hsp90–Sti1 (cpr6 and Sti1 as monomers) complex resulted in a
decrease in Sti1 binding in analytical ultracentrifugation experiments.
This supports earlier work, which showed that the binding of Sti1
displaced geldanamycin from the N-terminal nucleotide-binding site
of Hsp90 [19]. However, displacement of Sti1 wasmost pronounced in
the presence of p23 [25].
The ability of Hop/Sti1 to inhibit the ATPase activity of Hsp90
might be required for client protein loading [19]. Hsp70 in its low
afﬁnity client-protein binding state, represented by its ATP state,
would probably favor such a loading mechanism, and it would be
logical to assume that this would be a prerequisite for transfer of the
client protein from Hsp70 to Hsp90. However, the affect of Hop and
Sti1 on the ATPase activity of Hsp70 is variable. Hop from rabbit
reticulocytes has been shown to stimulate the ATPase activity of
Hsp70 [26]. It has also been shown that Hop could lower the Kd value
for the binding of ATP close to that of ADP and thus could act as a
nucleotide exchange factor [26]. Similarly, the activation of the ATPase
activity of Ssa1 (a yeast Hsp70) by Sti1 has been reported [27]. In
contrast the human Hop protein appears not to be an effecter of the
ATPase activity of Hsp70 and also does not act as a nucleotide
exchange factor, but simply prefers to bind Hsp70 in its ADP state [27].
Whatever the effect of Hop or Sti1 on the ATPase activity of Hsp70, the
release of the client protein must require that Hsp70 be converted to
an ATP-like state so the client protein can be released. The molecular
details of how this might be achieved are currently unknown.3.2. Cdc37
Another co-chaperone known to be involved in delivering client
proteins to the Hsp90 complex is Cdc37/p50. Like Hop/Sti1, Cdc37
also inhibits the ATPase activity of Hsp90 [28]. In this case, however,
the structural details for the molecular interactions between
Cdc37/p50 and Hsp90 are well documented [29]. Human Cdc37
(p50) prevents N-terminal dimerization by binding between the N-
terminal domains of Hsp90, interacting with the ATP lids them-
selves, thus physically blocking dimerization [29]. Furthermore, Arg
167 of Cdc37 hydrogen bonds with the catalytic Glu 33 residue of
Hsp90 and prevents it from carrying out hydrolysis of ATP (Fig. 4)
[29]. How exactly the client protein is transferred to Hsp90 and
whether Cdc37/p50 alters the conformation of the kinase to achieve
this is unknown.
Fig. 3. Model structure of Hop. Evidence suggests that although Hop/Sti1 may be dimeric in solution, in Hsp90 complexes Hop/Sti1 monomers may interact with Hsp90
independently. The TPR1 and TPR2a domains are shown bound with their Hsp70 and Hsp90 target peptides, respectively. Co-ordinates obtained as a kind gift from J. Guenter
Grossmann.
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Sgt1 is yet another co-chaperone that interacts with Hsp90 [30–
32] and also appears to be involved in client protein loading through
its ability to act as a hub for the formation of Hsp90 complexes [33–
38]. Sgt1 and Rar1 play a central role in the innate immunity
response in plants. Sgt1 has been found to associate with SCF E3
ubiquitin ligases, the CBF3 kinetochore complex, plant R proteins
and related animal Nod-like receptors [39–46]. Sgt1 consists of
three domains, an N-terminal TPR domain, a middle CS domain and
a C-terminal SGS domain. The TPR domain is homologous to other
TPR domains that bind the MEEVD motif of Hsp90. In this case,
however, the TPR-domain of Sgt1 binds Skp1 [46], and its CS domain
binds Hsp90 [46]. Themolecular details of this interaction have been
recently published [33]. The structure showed that the CS-domain
is, as expected, homologous to Sba1/p23, but unlike Sba1/p23 it
does not inhibit the ATPase activity of Hsp90 [33,46]. Consistent
with this, the CS domain of Sgt1 does not bind directly to the ATP lids
of Hsp90, as seen with Sba1. Thus, it does not inhibit the
conformational cycle in the same way that Sba1 does. Instead, the
CS domain of Sgt1 binds at a second site on the N-terminal domain of
Hsp90. Interestingly although it does not affect ATPase activity of
Hsp90 directly, it can recruit a second co-chaperone, Rar1 in plants,
Chp1 and melusin in mammals, which in the case for Rar1 has been
shown to be able to weakly stimulate the ATPase activity of Hsp90Fig. 4. Inhibition of the ATPase cycle by Cdc37/p50. Cdc37/p50 is shown in cyan and the
N-terminal domain of Hsp90 in green with a red ATP lid (pdb, 1US7). Arg 167 of
Cdc37/p50 interacts with the catalytic Glu 33 and prevents it from hydrolyzing ATP. The
non-hydrolysable analog of ATP, AMPPNP is shown in magenta. Hydrogen bonds are
shown as dotted blue lines.[34]. Rar1 consists of two CHORD domains (CHORD I and II), of
which each binds two zinc ions, whereas Chp1 and Melusin also
contain a C-terminal CS domain. However, the structure of the N-
terminal domain of Hsp90 in complex with the CS domain of Sgt1
and the CHORD II domain of Rar1 was recently published [34]. The
CHORD II domain consists of two lobes forming a cylindrical
structure (~54 Å long and ~13 Å in diameter). The C-terminal lobe
consists of a three-stranded antiparallel β-sheet covered on one side
by a short α-helix. The N-terminal lobe is devoid of secondary
structure, apart from a short β-strand, which makes an antiparallel
interaction with a β-strand extending from the C-terminal lobe,
crossing back onto the N-terminal lobe. Uniquely, the stimulation of
the ATPase activity by the CHORD II domain of Rar1 occurs while
Hsp90 is in an open conformation, resulting in a stable ADP bound
open state complex (Fig. 5a–b). The structure of this complex
revealed that the CHORD II domain might replace the ATP lid and
simultaneously modulate the catalytic loop of the middle domain to
achieve an activation of Hsp90. The Rar1 (CHORD II)–Hsp90–Sgt1
(CS domain) complexwas also shown to bemost stable in an Hsp90-
ADP state [34]. Thus, the Rar1 stimulated hydrolysis of ATP by Hsp90
would convert a Rar1–Hsp90–Sgt1 complex in to a stable ADP-
bound complex. As these complexes are involved in the innate
immunity response, in both plants and animals, it is interesting to
note that a stable complex could act as a long lived sensor for small
molecules from invasive organisms so that the host could act
immediately, without the delay of initiating transcription in the ﬁrst
instance. Thus, in this case client loading seems to occur onto a
stable inactive Hsp90 complex brought about by the action of Sgt1
and Rar1.
3.4. Sba1/p23
Unlike the above co-chaperones discussed so far, Sba1/p23 is not
involved in delivering client proteins to Hsp90. Instead it appears to
act to stabilize such complexes and the best example of this type of
complex is that of steroid hormone receptors. While Sba1/p23 can
bind Hsp90 in an apo state these co-chaperones show higher afﬁnity
for the ATP bound state of Hsp90 and therefore for its closed N-
terminally dimerized state [7,47]. The mechanism that Sba1 uses to
inhibit the ATPase activity of Hsp90 is somewhat different to that of
Hop and Cdc37. Unlike Sti1, Cdc37 and Sgt1, Sba1/p23 acts later on
in the ATPase cycle of Hsp90, which it appears to slow down.
Initially, it was puzzling as towhy yeast Sba1 only partially inhibited
(slowed) Hsp90 ATPase activity [15]. A more robust inhibition was,
however, seen with p23, the human homolog of Sba1 [47]. The
structure of the full-length yeast Hsp90 in complex with Sba1 and
AMPPNP helped to explain this observation (Fig. 6a) [10]. The
structure showed that while Sba1 binds to the closed N-terminally
Fig. 5. The stable Hsp90–Rar1 complex. a), Pymol cartoon showing the binding of the
CHORD II domain of Rar1 (cyan) to the N-terminal domain of Hsp90 (pdb, 2XCM; open
state, green; closed state, yellow ). The ATP lid in the open state is blue and in the closed
state it is red. The closed state of the ATP lid is incompatible with the binding of the
CHORD II domain. b), Pymol cartoon showing the interaction of the CHORD II domain of
Rar1 with the ADP bound Hsp90 (pdb, 2XCM). The N-terminal domain of Hsp90 is
shown in green with amino acids involved in binding ADP in salmon. CHORD II domain
is shown in cyanwith His 188 in yellow. ADP is shown in pale blue. Water molecules are
shown as red spheres and the magnesium ion as a cyan sphere. Hydrogen bonds are
shown as dotted blue lines.
Fig. 6. ATPase modulated states of Hsp90. a), The ‘inhibited’ state of Sba1 bound Hsp90
(pdb, 2CG9). Sba1 is shown in light blue with amino acid residues in cyan. The middle
domain of Hsp90 is shown in yellowwith amino acids residues in green. The N-terminal
domain sequences from the neighboring Hsp90 monomer are shown in gold. ATP is
shown bound to Arg 380 by hydrogen bounds (dotted blue lines). Trp 124 of Sba1 binds
into a hydrophobic pocket formed by the Hsp90 residues, Leu 315, Ile 388 and Val 391,
which signals the catalytic loop to be released into its active open conformation. This
state represents an ‘inhibited’ form of Hsp90 that is committed to hydrolyzing ATP. b),
Modulation of the catalytic loop of Hsp90. Hsp90 is shown in yellow (pdb2CG9; middle-
and C-terminal-domain not shown). The catalytic loop is shown in magenta (closed
state; pdb, 1HK7), green (partially open state of the N-domain Aha1 — middle domain
of Hsp90 complex, pdb 1USU) and the open active state (blue) of the Sba1-bound
structure (pdb 2CG9). Aha1 is in gold. The partially open state of the catalytic loop in the
N-Aha1 — middle-Hsp90 complex results because in this structure Arg 380 cannot
interact with ATP. Hydrogen bonds are shown as dotted blue lines.
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simultaneously causes the release and stabilization of the middle
domain catalytic loop in its active conformation. Consequently, the
complex is committed at some point to hydrolyzing the bound ATP.
Upon hydrolysis the complex would release Sba1, whose binding is
dependent on the closed N-terminally dimerized state of Hsp90.
Thus, Sba1 rather than halting the chaperone cycle, it uniquely
slows it down, perhaps regulating the time a particular client is held
in a speciﬁc conformation [10].
Recently, the structure of the CS domain of a variety of NudC and
NudC-like proteins has been published [48] or deposited in the pdb
database (Encephalitozoon Cuniculi NudC, human NudCL and NudCL2;
pdb ID 2O30, 1WGV and 2RH0, respectively). Like Sba1 and p23, the
human NudC has also been shown to be an inhibitor of the ATPase
activity of Hsp90. However, the precise molecular details have not yet
been established.3.5. The activator of Hsp90 ATPase, Aha1
The co-chaperone Aha1, like Sba1/p23, is not involved in client
protein loading. However, unlike Sba1/p23 it acts to accelerate the
ATPase cycle of Hsp90 and presumably the activation and maturation
of client proteins. Aha1 remains the most potent co-chaperone
activator of the ATPase activity of Hsp90 found to date [8,15]. The
N-terminal domain of Aha1 is known to be able to modulate the
catalytic loop of the middle domain of Hsp90, stabilizing it in an open
active-state. Full-length Aha1 is a signiﬁcantly more potent activator
of the ATPase activity. However, how it achieves this is yet to be
determined. Recently, it was shown that the C-terminal domain of
Aha1 binds to the dimerized N-terminal domains of Hsp90 [18]. It is
conceivable that here again we have anothermechanism bywhich the
ATPase activity of Hsp90 can be modulated. It is possible that the C-
terminal domain of Aha1 might either initiate N-terminal
Fig. 7.Model of the C-terminal small molecule-binding site of Hsp90. a), Pymol cartoon
showing the proposed site of interaction of novobiocin (cyan spheres) with the Hsp90
dimer (green and gold; co-ordinates were a kind gift from Brian S. J. Blagg. b), Proposed
interactions of novobiocin (cyan) with the C-terminal domains of Hsp90. Novobiocin is
bound close to the C-terminal dimerization interface of Hsp90 and makes contact with
both monomers of Hsp90 (green and gold). Hydrogen bonds are shown as dotted blue
lines.
619C. Prodromou / Biochimica et Biophysica Acta 1823 (2012) 614–623dimerization or may help to stabilize the N-terminally dimerized state
or the association of the N- and middle-domains of Hsp90 (Fig. 6b).
However, further structural and biochemical work is required to
categorically show the exact mechanism.
3.6. Tah1 and Pih1
Another co-chaperone that has been shown to activate the ATPase
activity of Hsp90 is Tah1. Tah1, together with Pih1 form part of the
chromosome remodeling complexes, Ino80 and SWR-C by interacting
with Rvb1 and Rvb2 [49], as well as interacting with RNA processing
factors, Rrp43p and Nop58p [50]. Activation by Tah1 of the Hsp90
ATPase activity is very weak [51], but has been conﬁrmed by another
study [52]. However, as a complex with Pih1, which binds to both
Tah1 and Hsp90, it inhibits the ATPase activity of Hsp90 [52].
Interestingly, this again appears to be a mechanism by which the
ATPase activity of Hsp90 is halted, thus allowing client protein loading
and complex formation.
3.7. Immunophilins
Cpr6, an immunophilin co-chaperone of Hsp90, has been shown to
weakly stimulate the ATPase activity of Hsp90 [15]. However, another
group has not yet conﬁrmed this activation and thus the details of
how this might occur and its signiﬁcance remain unknown. In
contrast, FKBP59 failed to stimulate the ATPase activity of Hsp90,
although it could stimulate the GR ligand-binding domain activated
activity of Hsp90 [47]. These results raise the important question of
whether other immunophilins (for example AIP/XAP2/ARA9) also
regulate Hsp90 ATPase activity and what purpose such activation
serves? The role of immunophilins in Hsp90 complexes is currently
held back by the fact that there are currently no known structures of
immunophilin complexes with Hsp90 as far as I am aware. However,
it is clear that immunophilins may not play a client-loading role in all
cases. In particular their incorporation into steroid hormone receptors
occurs after steroid hormone receptor loading onto Hsp90 [53,54].
3.8. Client protein activation
The ﬁrst report showing that activation of the weak ATPase activity
of Hsp90 was with the client protein ligand-binding domain of
glucocorticoid receptor [55]. However, in this study the ligand-binding
domain was found to be dimeric rather than monomeric. Untrans-
formed glucocorticoid receptor is found in cytosolic preparations as an
8–9 sv (Mr, 300,000) heteromeric complex consisting of a single
molecule of the receptor [56,57] and two molecules [58] of a non-
steroid-binding phosphoprotein, Hsp90 [59–66]. However, whether
ATPase activation of Hsp90 is a common feature for all client proteins
has not been established and it also raises the question of whether Sba1
would be able to stabilize complexes, which are actively hydrolyzing
ATP and thus promoting an open state conformation. For kinase
complexes the presence of Cdc37/p50 would promote an open inactive
state [28]. Whether, there are differences in the regulation of Hsp90
ATPase activity by different client proteins remains to be seen.
4. C-terminal domain ‘ATP binding site’
Clearly the ATPase activity of Hsp90 is important for the activation
of client proteins. Although, much of this process as we understand it
is due to the hydrolysis of ATP at the N-terminal domains of Hsp90, a
C-terminal ATP-binding site has also been reported [67–71]. However,
elucidation of the full-length structures of yeast Hsp90 [10], canine
Grp94 [72] and E. coli HtpG [73] do not obviously show an ATP-
binding site per se. The development of C-terminal inhibitors of Hsp90
suitable for the clinic has been hampered by the lack of a crystallo-
graphic structure of a smallmolecule bound to theC-terminal domain ofHsp90. There is, in fact,much interest in achieving this as such inhibitors
elicit unique effects on Hsp90's conformation, ATPase activity and its
interactions with co-chaperones and client proteins [69,70,74–82].
Recently a C-terminal binding site has been elucidated and a structure
bound with novobiocin modeled (Fig. 7a–b) [83]. Although this site
appears not to be an ATP-binding pocket with catalytic activity,
occupancy of this site by a small molecule prevents ATP-binding to
the N-terminal domain [70]. How this is achieved is not yet known, but
might involve co-operativity between theN- and C-terminal domains of
Hsp90 [84]. However, it is clear that the binding of a small molecule to
this site would disrupt the ability of Hsp90 to undergo N-terminal
dimerization. It might also prevent C-terminal dissociation of the C-
terminal dimerization domains [84]. This would not only inhibit the
ATPase conformational cycle of Hsp90, it would also disrupt the
interaction of speciﬁc co-chaperones and client proteins with Hsp90.
5. Post-translation modiﬁcations affecting the ATPase activity
5.1. Phosphorylation
The topic of post-translational modiﬁcations is treated compre-
hensively by Len Neckers and Mehdi Mollapour in this special edition
on Hsp90 in the chapter titled “Post-translational modiﬁcations of
Hsp90 and their contributions to chaperone regulation” .
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ATPase activity of Hsp90 and complex formation. A number of Hsp90
post-translational modiﬁcations have been detected that affect its
ATPase activity. Tyr 24 in yeast- and Tyr 38 in humanHsp90 have been
shown to be a common site upon which Hsp90 is phosphorylated [85]
(Fig. 8a–b). In yeast the tyrosine kinase responsible for this
phosphorylation was identiﬁed as Swe1Wee1 [85]. Mutation of Tyr
24 to a non-phosphorylatable phenylalanine residue had no affect on
its ATPase activity. However, mutation to a glutamate, a potential
mimetic of the phosphorylated state, almost completely abolished
Hsp90 ATPase activity. In vivo, as sole Hsp90, Y24E and Y24D mutants
could not support viability due to their low ATPase activity. However,
using the nonphosphorylatable mutants, Y24F and Y38F, indicated
that phosphorylation at this site is important for productive
chaperoning of kinases and for suppressing heat shock factor activity,
but had minimal affect on the chaperoning of steroid hormone
receptor client proteins. Thus, a mechanism by which Hsp90 could be
targeted to speciﬁc groups of client proteins could operate by
modulation of the phosphorylated state of Tyr 24 in yeast and Tyr
38 in human cells.
Another phosphorylation site that has been identiﬁed is Thr 22 in
yeast and Thr 36 in human Hsp90 [86]. The phosphorylation of Thr 22
and Thr 36 was shown to be dependent on casein kinase II activity.Fig. 8. Sites of post-translational modiﬁcation of Hsp90. a), The closed active
conformation of yeast Hsp90 showing amino acid residues that are phosphorylated
(Thr 22 and Tyr 24), acetylated (K294), nitrosylated (Cys 598 In Hsp90α; equivalent
position in yeast Hsp90 is Ala 577) and involved in client protein binding (Trp 300). ATP
and selected amino acid residues are shown as gold and cyan spheres, respectively. b),
Position of amino acid residues (Thr 22 and Tyr 24, yellow) in the open state of the N-
terminal domain of yeast Hsp90. ATP is shown in spheres. Hydrogen bounds are shown
as dotted blue lines.Like Tyr 24, Thr 22 forms part of an interacting group of residues that
come together to form important interactions with the catalytic-loop
residue Leu 378, from the neighboring monomer of Hsp90 (Figs. 1c
and 6a). A previously described mutation T22I, originally isolated as a
temperature sensitive mutation in yeast [87], was shown to increase
the ATPase activity of Hsp90 [9]. The increased hydrophobicity of the
T22I mutation and its interaction with the catalytic-loop residue Leu
378, are consistent with this mutation stimulating the ATPase activity
of Hsp90. Mutation of Thr 22 to alanine does not affect the ATPase
activity of Hsp90, however, mutation to glutamate, a possible
phosphomimetic mutation, resulted in a decrease in the ATPase
activity of Hsp90 [86]. As with the Y24E mutation, the T22E mutant
showed differential effects on the chaperoning of speciﬁc client
proteins. Thus, a negative affect was seen on the chaperoning of v-Src
and Ste11, whereas glucocorticoid receptor (GR) activation was
increased by approximately four-fold and the stability of the cystic
ﬁbrosis transmembrane regulator (CFTR) was improved. In the case
for the human mutation, T36E, loss of interaction with v-Src, Raf1,
ErbB2, Cdk4 and GR was observed, whereas CFTR protein levels
increased.
Changes in the association of client proteins with phosphorylated
Hsp90 might occur due to direct effects on their association or
indirectly due to effects on co-chaperone interaction with Hsp90.
With Y24F and wild type Hsp90 in a Swe1Δ background the
association of Aha1 was completely abolished, sba1 interaction
reduced, while Cdc37/p50 and Sti1/Hop association was unaffected
relative to wild type Hsp90. A similar situation was found using the
human Y38F mutant. Effects on co-chaperone interactions with the
T22A and T22E mutants were also seen. The association of Aha1 was
completely abolished, while that of Cdc37 was reduced. Interactions
with Sti1 and Sba1were unaffected. Similar results were seenwith the
human T38A and T38E mutants. Aha1 association was completely
diminished, while that of p50 was mainly reduced with the T38E
mutant. Hop interaction was again unaffected, but p23 interaction
was slightly reduced. Thus, these results suggest that changes in the
phosphorylation state of Hsp90 could target the chaperone to distinct
types of complexes.
The list of Hsp90 phosphorylation sites identiﬁed is now fairly
extensive (see [88]) and is probably beyond the scope of this review.
However, the examples above raise the possibility that phosphory-
lation of Hsp90 acts to modulate the conformational cycle of Hsp90
and thus mold the chaperone cycle to speciﬁc client proteins. This is
an interesting point as the clientele of Hsp90 are structurally very
varied and would have speciﬁc requirements for their maturation and
activation. However, changes in the chaperone cycle of Hsp90 could
result by a number of mechanism including direct changes in the
ATPase activity of Hsp90, changes in its interaction with co-
chaperones or its clientele.
5.2. Acetylation
Hsp90 acetylation has also been reported [89–92], however, affects
on the ATPase activity of Hsp90 have not been determined. A direct
functional analysis at one speciﬁc site, Lys 294 of yeast Hsp90, has
been carried out [91] (Fig. 8a). Mutations, mimicking acetylation at
this site, K294Q and K294A, drastically reduced interaction with
ErbB2, V-Src, mutant p53 and HIF1α, suggesting a universal impact on
Hsp90 interaction with client proteins. Interestingly, Lys 294 lies close
to, and on the same face, as Trp 300, which was previously identiﬁed
as a client protein-binding site in the middle domain of Hsp90
(Fig. 8a) [93]. Mutation at this site did not affect Hsp90 ATPase
activity, but caused severe defects in growth and v-Src activation at
30 °C and was lethal at 37 °C. Comparing co-chaperone associations
between the conservative mutation, K294R, and the acetylation
mimetic mutants, K294Q and K294A, showed that interactions were
altered. Interactions with p23, p50, p60, Hsp70 and CHIP were all
Fig. 9. Radicicol resistance by modiﬁcation of the ATP-binding site of Hsp90. A single
mutation, L34I results in the opening of a pocket that alters the water structure of the
active site. Three additional water molecules enter and repel the chlorine (Cl) of
radicicol thus decreasing its afﬁnity for Hsp90. Water molecules are shown as pale
yellow (L34I) and cyan (wild type) spheres. Radicicol bound to the mutant protein is
shown in yellow while that bound to wild type Hsp90 is in cyan. Amino acid residues of
L34I are in yellow and residues of the wild type protein are in cyan. Mutations are
shown as L34I and V35I in red text. Dotted red (L34I) and blue lines (wild type)
represent hydrogen bonds.
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K294Q was only slightly affected, relative to wild type Hsp90.
Association of Aha1 and FKBP52 was completely abolished with
K294A and K294Q, while the K294R mutant showed increased
interactions. Clearly, as with phosphorylation effects on client protein
associations might be either direct or indirect due to changes in co-
chaperone associations with Hsp90. However, it is clear that
acetylation plays an important role in regulating Hsp90 complex
formation and perhaps at a universal level.
5.3. S-nitrosylation
S-nitrosylation of Cys 598 is another post-translational modiﬁcation
that has been observed for human Hsp90α [94,95]. S-nitrosylation of
Hsp90α results in the inhibitionof itsATPaseactivity andadecrease in the
ability to activate eNOS [95]. A similar inhibition of activity has been seen
in the nitrosylated mutant, A577C, of the yeast Hsp90 protein (Fig. 8a)
[94].MutationofAla 577 to either isoleucineor asparigine appears to alter
the dimerization of the C-terminal and N-terminal domains and
consequently would affect client protein activation and co-chaperone
association, but as far as I am aware this has not been studied in detail.
6. Mechanisms of drug resistance compatible with Hsp90 ATPase
activity
Hsp90 has been the subject of intense research to develop potent
inhibitors that are effective against cancer and a number of drugs have
entered clinical trials (recently reviewed in [96]). The conservation of
the Hsp90 N-terminal domain residues involved in ATP binding and
hydrolysis is high. The ATPase activity of Hsp90 is also essential for the
viability of cells [97]. Together, this suggests that mutations of
residues involved in the ATPase activity of Hsp90 that lead to drug
resistance are unlikely. So far resistance to 17-AAG has been seen in
cells with low NAD9P0H/quinone oxidoreductase I (NQ01) activity
[98–100]. NQO1 affects the degree of intracellular reduction of these
inhibitors to the hydroquinone, a reduced state in which they are
more potent inhibitors of Hsp90 [100]. Resistance is also seen by
overexpression of P-glycoprotein and/or MRP-1 [101,102]. However,
resistance due to point mutations of the active site of Hsp90 has so far
not emerged from the clinic.
For radicicol a single point mutation has been identiﬁed, L34I
(yeast Hsp90) that leads to a partial resistance against radicicol
binding, while preserving the binding of ATP and the ATPase activity
of the protein. Thus, in all probability interactions with client proteins
and co-chaperones are likely to be unaffected, although this was not
tested. The molecular basis for resistance is due to changes in the
water structure of the ATP-binding domain that repel the chlorine
atom of radicicol (Fig. 9). The L34I mutation showed no cross-
resistance to geldanamycin. Other point mutations that lead to
resistance include Hsp90α I123T and A121N and Hsp90β I128T,
A116N and T31I [103,104]. It appears that the increased resistance
seen with such mutants might be due to enhanced interactions with
Aha1 [103]. In fact, depleting the levels of Hsp90 co-chaperones such
as Aha1, Cdc37 and p23 have been shown to increase resistance to
Hsp90 inhibition in cells [105–107].
Like radicicol, geldanamycin is also a naturally produced antibiotic.
Consequently it is highly likely that mechanisms involving the
alteration of the ATP-binding site of Hsp90 exist. However, the lack
of any mutations seen in the clinic, is not only encouraging from a
clinical point of view, but suggests that these changes are likely to be
complex in nature (see note as supporting evidence).
7. Concluding remarks
The conformational changes in Hsp90 are central to its role as a
chaperone and co-chaperones play an important role in regulatingthem. Initiated by the binding of ATP these structural changes are
subject to a whole host of regulatory mechanisms. The question of
whether these changes are coupled or not, depends on the situation
and the precise layer of regulation at that time. The current evidence
suggests that the co-chaperones play a number of different roles in
Hsp90. To date, co-chaperones have been identiﬁed that are
responsible for the loading of client protein. These include Hop/Sti1,
Cdc37/p50, Tah1–Pih1 complex and Sgt1–Rar1 complex. Others
activate the ATPase activity of Hsp90. The most potent of these is
Aha1, and it is presumed that Aha1 acts to increase the rate of
activation and maturation of client proteins. Finally, we see that Sba1
acts to slow and stabilize client protein complexes and here we
assume that the client might be stabilized in a particular conformation
in an activatable state. The complex set of structural changes required
to bring about a catalytically active state of Hsp90 has allowed a
cohort of different regulatory co-chaperone mechanisms to act on
Hsp90. However, the ‘great unknown’ that remains in understanding
the Hsp90 chaperone cycle is what the conformational changes of
Hsp90 do to activate or cause the maturation of client proteins. This
major question needs to be addressed to further advance our
understanding of the Hsp90 chaperone cycle.
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